← Leaderboards
Robyn Therese Domsic
University Of Pittsburgh At Pittsburgh
$4,058,832
Attributed
$4,386,508
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $507.8K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,386,508 · 6
By mechanism
P50$2,132,116 · 2
R01$1,272,672 · 2
K23$611,451 · 1
R21$370,269 · 1
Top collaborators
- Dana P Ascherman3 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Dana P Ascherman$3,212,537
- Milos Hauskrecht$3,805,461
- Kathryn S. Torok$2,024,095
- Heidi T Jacobe$1,705,648
- Carol A Feghali-Bostwick$17,984,586
Others in their field
Top investigators on “Autoimmune Diseases”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$303,553,812
- Barton F Haynes · Duke University$175,178,961
- Jeffrey P Krischer · University Of South Florida$145,926,425
- Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason$84,524,613
- Mark S Anderson · University Of California, San Francisco$70,760,032
- Robert S Negrin · Stanford University$48,464,292
Research focus
Autoimmune DiseasesOrganCohortUniversitiesAutoantibodiesDiffuse SclerodermaSkinSystemic SclerodermaBlood VesselsSclerodermaMortalityRheumatismSymptomsDatabasesAffectDesignRecording Of Previous EventsResourcesSpecimenLinkSerumBasePathogenesisProspective
Grant awards (22)
Clinical and Biorepository Core$234,491
P50 · FY2025 · AR · contact PI
Clinical and Biorepository Core$270,300
P50 · FY2024 · AR · contact PI
Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease$237,514
R01 · FY2024 · AR · contact PI
Clinical and Biorepository Core$270,300
P50 · FY2023 · AR · contact PI
Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease$209,880
R01 · FY2023 · AR · contact PI
Clinical and Biorepository Core$270,300
P50 · FY2022 · AR · contact PI
Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease$207,958
R01 · FY2022 · AR · contact PI
Core 1: Clinical and Biological Specimen Core$227,121
P50 · FY2021 · AR · contact PI
Core 1: Clinical and Biological Specimen Core$227,121
P50 · FY2020 · AR · contact PI
Addressing Critical Knowledge Gaps in Early Diffuse Scleroderma Trial Design$206,580
R01 · FY2020 · AR · contact PI
Core 1: Clinical and Biological Specimen Core$227,121
P50 · FY2019 · AR · contact PI
Core 1: Clinical and Biological Specimen Core$218,315
P50 · FY2018 · AR · contact PI
Addressing Critical Knowledge Gaps in Early Diffuse Scleroderma Trial Design$206,140
R01 · FY2018 · AR · contact PI
Addressing Critical Knowledge Gaps in Early Diffuse Scleroderma Trial Design$204,600
R01 · FY2017 · AR · contact PI
Core 1: Clinical and Biological Specimen Core$187,047
P50 · FY2017 · AR · contact PI
Effect of Atorvastatin on Endothelial Function and Raynaud in Diffuse Scleroderma$168,655
R21 · FY2016 · AR · contact PI
Effect of Atorvastatin on Endothelial Function and Raynaud in Diffuse Scleroderma$201,614
R21 · FY2015 · AR · contact PI
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma$124,929
K23 · FY2014 · AR · contact PI
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma$124,929
K23 · FY2013 · AR · contact PI
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma$123,309
K23 · FY2012 · AR · contact PI
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma$120,504
K23 · FY2011 · AR · contact PI
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma$117,780
K23 · FY2009 · AR · contact PI